- Home
- SACH vs APLT Comparison
SACH vs APLT Comparison
Compare SACH & APLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SACH
- APLT
- Stock Information
- Founded
- SACH 2010
- APLT 2016
- Country
- SACH United States
- APLT United States
- Employees
- SACH N/A
- APLT N/A
- Industry
- SACH Real Estate Investment Trusts
- APLT Biotechnology: Pharmaceutical Preparations
- Sector
- SACH Real Estate
- APLT Health Care
- Exchange
- SACH Nasdaq
- APLT Nasdaq
- Market Cap
- SACH 54.9M
- APLT 62.9M
- IPO Year
- SACH 2017
- APLT 2019
- Fundamental
- Price
- SACH $1.15
- APLT $0.46
- Analyst Decision
- SACH Hold
- APLT Buy
- Analyst Count
- SACH 4
- APLT 6
- Target Price
- SACH $2.25
- APLT $6.10
- AVG Volume (30 Days)
- SACH 121.5K
- APLT 1.2M
- Earning Date
- SACH 08-05-2025
- APLT 08-19-2025
- Dividend Yield
- SACH 17.70%
- APLT N/A
- EPS Growth
- SACH N/A
- APLT N/A
- EPS
- SACH N/A
- APLT N/A
- Revenue
- SACH N/A
- APLT $265,000.00
- Revenue This Year
- SACH N/A
- APLT $415.60
- Revenue Next Year
- SACH $4.98
- APLT $1,323.96
- P/E Ratio
- SACH N/A
- APLT N/A
- Revenue Growth
- SACH N/A
- APLT N/A
- 52 Week Low
- SACH $0.80
- APLT $0.30
- 52 Week High
- SACH $2.70
- APLT $10.62
- Technical
- Relative Strength Index (RSI)
- SACH 46.02
- APLT 52.29
- Support Level
- SACH $1.10
- APLT $0.42
- Resistance Level
- SACH $1.21
- APLT $0.48
- Average True Range (ATR)
- SACH 0.04
- APLT 0.04
- MACD
- SACH -0.01
- APLT -0.01
- Stochastic Oscillator
- SACH 30.63
- APLT 33.13
About SACH Sachem Capital Corp.
Sachem Capital Corp is a real estate investment trust. The company specializes in originating, underwriting, funding, servicing, and managing a portfolio of short-term loans secured by first mortgage liens on real property located in Connecticut. Its primary objective is to grow the loan portfolio while protecting and preserving capital in a manner that provides for attractive risk-adjusted returns to shareholders over the long term through dividends. The company earns majority of its revenue through Interest income from loans.
About APLT Applied Therapeutics Inc.
Applied Therapeutics Inc is a clinical-stage biopharmaceutical company, developing a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need. The company's drug compounds pipeline includes AT-007 which is a novel central nervous system, penetrant ARI that it is developing for the treatment of rare metabolic diseases, including Galactosemia and Sorbitol Dehydrogenase (SORD) Deficiency, AT-001 for the treatment of diabetic cardiomyopathy, and AT-003 for the treatment of diabetic retinopathy.